Britain and America have finalized a important bilateral deal that will ensure no import taxes on British drug products going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has committed to increase spending on medicines through the National Health Service (NHS). This commitment ensures that duties on these key goods will be held at nothing for a period of the next three years.
This agreement comes after previous warnings to dramatically increase duties on branded pharmaceutical imports, with figures discussed as high as double the cost.
"This agreement with the United Kingdom reinforces the global environment for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. medicine commerce," an announcement declared.
Economic Importance
Pharmaceuticals are one of the UK's largest goods shipped to the America, which is by far the biggest buyer for major British pharmaceutical firms.
Trade data indicate that in the 12 months leading up to last September, the UK exported pharmaceutical products totaling billions to the US. This amount accounted for a significant portion of all goods exports in that span.
"This guarantee safeguards jobs, stimulates capital expenditure and sets the stage for the UK to become a worldwide center for medical research," a minister remarked.
Key British Pledges
The deal entails several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to raise overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments exceeded 20%.
Industry Background
This agreement comes amid a long-running row between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that American customers were paying a premium for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official stated that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
